Shenzhen Zhongmei Kangshi Biotechnology Co., Ltd.

Shenzhen Zhongmei Kangshi Biotechnology Co., Ltd. (hereinafter referred to as Zhongmei Kangshi) was established in March 2008 in Nanshan High-tech Park, Nanshan District, Shenzhen. It is one of the earliest high-tech enterprises to initiate the industrialization of tumor biological immunotherapy technology. The company is dedicated to technology research and development, technology transformation, hospital technical cooperation, and international and domestic patient services. More than 90% of the company's employees have a bachelor's degree or above, and scientific research and technical personnel account for more than 40%.
Tumor biological immunotherapy technology (mainly referring to CTL cells, DC tumor vaccines, CIK cells, DCCIK cells, NK cells, TIL cells, TCR, CAR-T cells, microtransplantation, etc.) is a high-tech approach to tumor treatment in the 21st century. Unlike radiotherapy and chemotherapy for tumor treatment, tumor biological immune cell therapy technology has significant advantages such as remarkable efficacy, low or no toxic side effects, and no drug resistance. Therefore, it has become an important component of comprehensive tumor treatment and one of the forward-looking technologies in the development of oncology. In the summary report of the 2000 American "International Symposium on Cancer Biology/Immunotherapy and Gene Therapy," it was pointed out: "Biotherapy is currently known as the only treatment method expected to completely eliminate cancer cells, and the 21st century is the era of tumor biotherapy."
On October 3, 2011, the Nobel Prize Committee of the Karolinska Institute in Sweden announced that the 2011 Nobel Prize in Physiology or Medicine would be awarded to three scientists from the United States, France, and Canada in recognition of their contributions to the study of the human immune system. The review committee believed that the three winners this year discovered the key principles of immune system activation, which revolutionized people's understanding of the immune system. Among them, Canadian scientist Ralph Steinman received half of the 2011 Nobel Prize in Physiology or Medicine for his achievements in "the discovery of dendritic DC cells and their role in the adaptive immune system." Rockefeller University, where Steinman worked, issued a statement saying: Four years ago, Steinman was diagnosed with pancreatic cancer. He had been using his own invented cell immunotherapy based on dendritic cell stimulation (DC tumor vaccine) to treat himself, allowing his life to continue, creating a miracle.
On June 7, 2012, the New England Journal of Medicine published an article "200 Years of Cancer Research," clearly stating that tumor treatment methods have changed from the three-pronged approach of surgery, radiotherapy, and chemotherapy to the four-pronged approach of surgery, radiotherapy, chemotherapy, and biological immunotherapy.
On December 21, 2012, the American journal Science listed "tumor immunotherapy" as one of the six scientific fields most worthy of attention in 2013. The six scientific fields worthy of attention are single-cell sequencing, Planck's detection of microwave background radiation, the Human Connectome Project, exploration of the subglacial world in Antarctica, cancer immunotherapy, and basic plant research.
On December 29, 2012, the State Council's notice on issuing the biological industry development plan (Guo Fa [2012] No. 65) explicitly listed anti-tumor drugs, therapeutic vaccines, cell therapy, etc. as important industries for development and key support. From 2013 to 2015, the average annual growth rate of the biological industry output value remained above 20%. By 2015, the added value of the biological industry as a proportion of GDP doubled compared with 2010, and the industrial value-added rate increased significantly.
On December 19, 2013, the American journal Science rated cancer immunotherapy as the top of the world's top ten scientific breakthroughs in 2013. In the same year, Science Translational Medicine pointed out that cell therapy would become the future "third pillar of medicine." At present, immunotherapy in developed countries has become the only treatment option, regarded as a promising method to cure tumors, and will cover 60% of cancer patients, with an estimated annual market share of 50 billion US dollars.
In October 2014, Zhongmei Kangshi received a strategic investment of 204 million yuan from the listed company Beilu Pharmaceutical and became a listed company.
At present, Zhongmei Kangshi has achieved a leading advantage in the field of tumor biological immunotherapy technology and has a comprehensive sustainable technology research and development innovation system and a world-class scientist team. Zhongmei Kangshi has established three research and development center laboratories and one cell preparation process optimization research and development center laboratory in Beijing, Shanghai, and Shenzhen, and possesses multiple internationally leading independent intellectual property tumor immune cell therapy technologies:
(1) 50ml peripheral blood serum-free culture DCCIK cell technology;
(2) Multi-target memory mCTL cell technology;
(3) Multi-target multifunctional mDC vaccine technology;
(4) NK cell technology;
(5) Super granulocyte anti-cancer technology;
(6) TIL tumor-infiltrating cell anti-tumor technology;
(7) CAR-T cell technology;
(8) Microtransplantation and other reserve technologies.

Advantages of Zhongmei Kangshi:
Listed company, the most reputable
One of the earliest companies to initiate and focus on industrialization in this field, committed to leading the professional and standardized development of this industry
Possesses a stable organizational management system and a professional and high-quality elite team
Possesses multiple original and core technologies and a sustainable research and development innovation system
Possesses clinical research data of exclusive original technology published in internationally authoritative medical journals
Possesses the ability to export technology to developed countries such as the United States
Possesses an immune cell therapy standard management system adopted by the US FDA
Possesses an international and domestic high-level academic development platform and the ability to lead international multicenter clinical research with participation from the United States and other countries
Possesses the largest domestic hospital cooperation operation platform
Possesses a clinical and patient service platform for international patients to receive treatment in China
Zhongmei Kangshi adheres to the corporate culture concept of "rigorous, innovative, responsible, caring" and the core value of "innovative technology, protecting life," and is committed to leading the development of tumor biological therapy technology. At present, Zhongmei Kangshi is a high-tech enterprise, an ISO9001 international quality system certification enterprise, a member unit of the International Society for Biological Cell Therapy, a council member unit of the China Biological Technology Association, and a CSCO member unit.
The company has now entered a track of rapid development, and its business has expanded to major first-tier provinces and cities across the country. We sincerely invite outstanding talents with ideals and ambitions to join the company, develop together with the company, and devote themselves to the great cause of fighting tumors, which has extraordinary significance and value!
Company values: innovative technology, protecting life
Corporate culture concept: rigorous, innovative, responsible, caring
Company mission: fight tumors, benefit mankind; care for employees, give back to society
Company vision: become an international high-end integrated platform for biological cell research and development, technology, products, and services that is professional and integrated!
We provide:
1. Working hours: five-day work system, with national statutory holidays;
2. Employees enjoy the national "five insurances and one housing fund" from the first day of joining the company;
3. Enjoy multiple benefits and employee protections;
4. Provide professional technical and management training, a humanized corporate culture atmosphere, broad development space, and flexible and diverse promotion channels.
Due to the development of the company's business, we are urgently recruiting the following high-end positions. Everyone is welcome to recommend and apply.
The company's high-end positions and salaries for these positions:
1. Marketing Director: annual salary 500,000-800,000 yuan, year-end option incentives
2. Marketing Department Manager: annual salary 300,000-500,000 yuan, year-end option incentives
3. Product Manager: annual salary 250,000-400,000 yuan, year-end option incentives
4. Business Manager: annual salary 200,000-400,000 yuan, year-end option incentives
5. Operations Department Project Manager: annual salary 150,000-300,000 yuan, year-end option incentives
6. Regional Director: annual salary 400,000-600,000 yuan, year-end option incentives
7. Regional Sales Manager (Operations Center Manager): annual salary 200,000-400,000 yuan, year-end option incentives
8. Corporate Planning and Marketing Department Manager: annual salary 200,000-300,000 yuan, year-end option incentives